Zhitong Finance App News, Chuangsheng Group Pharmaceutical-B (06628.HK) issued an announcement relating (including) to the sale of CDMO assets to the buyer (a wholly-owned subsidiary of WuXi Biologics) at a total cost of RMB 190 million. As of the date of this announcement, the Group has received the net amount of the initial payment of consideration from the buyer after tax in accordance with the terms of the asset purchase agreement. Proceeds collected will be used to supplement the Group's general working capital and develop the Group's product pipeline.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.